Question 1

What is the difference between Ibrance and Kisqali?

Accepted Answer

Ibrance is Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer. and is developed by Pfizer. Kisqali is Ribociclib inhibits CDK4/6 kinases to arrest G1 cell cycle phase; letrozole inhibits aromatase to reduce estrogen biosynthesis. and is developed by Novartis.

Question 2

What are Ibrance and Kisqali used for?

Accepted Answer

Ibrance: Hormone receptor positive malignant neoplasm of breast, Human epidermal growth factor 2 negative carcinoma of breast. Kisqali: Hormone receptor positive malignant neoplasm of breast.

Question 3

Are Ibrance and Kisqali in the same drug class?

Accepted Answer

No — Ibrance is CDK4/6 inhibitor and Kisqali is CDK4/6 inhibitor; aromatase inhibitor.

	Ibrance	Kisqali
Generic name	Palbociclib	ribociclib
Sponsor	Pfizer	Novartis
Drug class	CDK4/6 inhibitor	CDK4/6 inhibitor; aromatase inhibitor
Molecular target	Cyclin-dependent kinases 4 and 6 (CDK4/6)	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme
Modality	Small molecule	—
Phase	FDA-approved	FDA-approved
Therapeutic area	Oncology	Oncology
First approval	2015	2017

Ibrance vs Kisqali

At a glance

Mechanism of action

Approved indications

Ibrance

Kisqali

Common side effects

Ibrance

Kisqali

Further reading

Ibrance	Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer.
Kisqali	Ribociclib inhibits CDK4/6 kinases to arrest G1 cell cycle phase; letrozole inhibits aromatase to reduce estrogen biosynthesis.